EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

Rationale and Design for ALPHA-ORBIT: a phase 3 trial of navenibart, a monoclonal antibody inhibitor of plasma kallikrein for participants with hereditary angioedema (HAE)

Sunday 15 Jun, 12:45 PM - 12:45 PM Glasgow, United Kingdom